Regron

Genocore-Biotech.com Announce Decision to Advance Long-Acting Hemophilia B Therapy into a Registrational Trial

The potential of this new therapy is to prolong protection from bleeding and reduce the frequency of injections.

<p><strong>23, December 2015:</strong> Genocore Biotech (ISIN:CN1000007515), an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody (mAbs), today announced that they plan to advance the companies&rsquo; Hemophilia B therapy a registrational clinical trial in hemophilia B patients. The decision to advance the program is based on promising data from a pharmacokinetic study in severe, previously-treated hemophilia B patients. In addition, the therapy demonstrated a prolonged half-life compared to historical data for existing therapies, supporting advancement of the program.</p> <p align="center"><img title="logo Genocore-Biotech-com" src="http://oi67.tinypic.com/20gmlvp.jpg" alt="logo Genocore-Biotech-com" /></p> <p align="/center">&nbsp;</p> <p>Hemophilia B requires frequent injections, creating a significant burden for the majority of individuals with the disorder. The potential of this new therapy, which is based on <strong><a title="Genocore" href="http://genocore-biotech.com/en/">Genocore</a></strong> Biotech&rsquo;s novel and proprietary technology, is to prolong protection from bleeding and reduce the frequency of injections for both prophylaxis and on-demand therapy will be evaluated in the registrational trial.</p> <p>The global trial is being designed to assess the safety, pharmacokinetics and efficacy of the new therapy in the prevention and treatment of bleeding in hemophilia B patients.</p> <p>&ldquo;The treatment is an example of Genocore Biotech&rsquo;s commitment to developing innovative therapies to address significant unmet medical needs. The program has the potential to improve the lives of individuals with hemophilia B and we are excited about advancing the program,&rdquo; said Mr. Wang Yen Horng, president and CEO of Genocore Biotech.</p> <p>"The results are very encouraging. The decision to initiate our first registrational program represents true progress in our efforts to offer hemophilia B patients treatment that makes a significant difference and is also an important milestone,&rdquo; Ming Koo Director of Medical Research at Genocore Biotech.</p> <p><strong>About Genocore-Biotech.com:</strong></p> <p><strong><a title="Genocore-Biotech.com" href="http://genocore-biotech.com/en/">Genocore-Biotech.com</a></strong> is an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody (mAbs) and Fc-fusion protein drugs. With a total investment of about 95 million USD, about 110 employees and R&amp;D lab, Process Development lab, Analytical &amp; Quality center, and a cGMP clinical production facility the firm is a respectable player in the medical industry. Genocore Biotech has a highly experienced and well-integrated expert team whose expertise covers all the key steps of mAb drug research and development. They have on average 15-20 years of hand-on working experience at leading western biopharmaceutical companies.</p> <p><strong>For Media Contact:</strong></p> <p>Company: Genocore-Biotech.com</p> <p>Address: Excellence Century Plaza</p> <p>Tower 1, Fuhua 3rd Road, Futian District</p> <p>Shenzhen, People's Republic of China</p> <p>Tel: +86 755 330 595 45</p> <p>Email: media@genocore-biotech.com</p>

Regron

Mumbai,
India

Newsletter

Powered by PRNEWS.io